A multidisciplinary team of scientists share recent advancements in innovative in-vitro cancer biology methods for screening drug-like molecules in cancer tissue relevant models in a new report published online ahead-of-print at SLAS Discovery. Entitled Advanced Development of Primary Pancreatic Organoid Tumor Models for High-Throughput Phenotypic Drug Screening, the report can be accessed for free.
Santosh Paidi, a graduate research assistant in the Department of Mechanical Engineering and at Johns Hopkins University, has been selected as the 2018 recipient of the SLAS Graduate Education Fellowship Grant. The $100,000 SLAS fellowship grant, awarded over two years, allows Paidi to continue his work in the lab of Ishan Barman, Ph.D., which employs vibrational spectroscopy and recent improvements in areas such as optics, nanotechnology and computing, to develop improved diagnostic tools that can provide rapid, robust, quantitative and molecular-specific readouts from biological specimen.
A new original research report available ahead-of-print at SLAS Technology demonstrates the semi-automation of a GlycoWorks RapiFluor-MS (RFMS) Kit using a pipetting robot to improve life sciences research productivity.
In the April 2018 issue of SLAS Technology, Breitwieser and colleagues of the Karlsruhe Institute of Technology (Germany) describe a fully automated high-throughput sorting system for zebrafish embryo phenotypes that benefits high-throughput screening by saving time and improving accuracy.
A review article by Prof. Stefan Broer, Ph.D., highlights opportunities and challenges in using amino acid transporters as drug targets. Amino Acid Transporters as Disease Modifiers and Drug Targets provides an overview of methods used to identify new inhibitors for amino acid transporters and outlines cell and organ function where these can be used to modulate, prevent or to treat diseases.
A perspective article in the March 2018 issue of SLAS Discovery from the biology group at the European Screening Centre Newhouse details how the European Lead Factory (ELF), a large publicly accessible drug discovery platform, uses microscale thermophoresis (MST) to aid in the prioritization of small molecule hits from high-throughput screening.
SLAS Discovery (formerly the Journal of Biomolecular Screening) and SLAS Technology (formerly the Journal of Laboratory Automation), both published by SLAS (Society of Laboratory Automation and Screening) in partnership with SAGE Publishing, hosted a special reception to celebrate the 2018 SLAS Journal Achievement Award honorees on Feb. 6 at SLAS2018, the SLAS International Conference and Exhibition, held Feb. 3-7, 2018, in San Diego, CA.
Three organizations earned a SLAS New Product Award yesterday at SLAS2018 in San Diego for their innovative new productsthat have played an important role in the advancement of life sciences drug discovery and development.
SLAS2018 was all about science and innovation as new keynote lectures, cutting-edge podium presentations and the new SLAS Ignite Theater series stoked the collaborative nature of today's life sciences professionals with three days of ground-breaking presentations that left attendees pondering new ways to keep pace with the speed of science.
A phenotypic high-throughput screen to identify modulators that improve mutant cystic fibrosis transmembrane conductance regulator (CFTR) activity is described in the SLAS Discovery February 2018 front cover feature article by Giuliano and colleagues of Proteostasis Therapeutics, Inc. (Cambridge, MA).
“The 2018 SLAS Technology Ten represent some of the most innovative scientific achievements that were featured in SLAS Technology in the past 12 months,” says Editor-in-Chief Edward Kai-Hua Chow, PhD (National University of Singapore).
Life sciences professionals and business development dealmakers from all walks of industry, academia and government have a new interchange at SLAS2018 – SLAS Ignite, a series of programs that foster scientific innovation through collaboration, debuts at the 2018 SLAS International Conference and Exhibition (SLAS2018), Feb. 3-7, in San Diego, CA.
A new article in the February 2018 issue of SLAS Technology describes a new platform that could change the way cancer is diagnosed and treated by automating the isolation of circulating tumor cells (CTCs) directly from cancer patient blood. This article provides unique insight into the development of a commercial system that has the potential to change the standard of care in cancer diagnosis and treatment.
A new original research article in SLAS Discovery presents a fast, sensitive, and robust methodology for screening small molecule inhibitors against CD73/Ecto-5’-Nucleotidase, a promising target for developing anti-cancer drugs.
Jill Hronek, Director of Marketing Communications
Telephone: +1.630.256.7527, ext. 103